E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
- Status
- COMPLETED
- Phase
- PHASE2
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE2
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE3
Treatment Optimization in Patients With Untreated Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2